alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–99 of 99 studies with an author at University of Exeter (GB) (page 4 of 4) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 99 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer's research & therapy 2021-10-11

Rare variants should only be investigated in users with a family history of early-onset dementia in a first degree relative. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus

✓ Peer-reviewed alzhub usefulness score 50 out of 100. International psychogeriatrics 2018-08-02

ABSTRACTObjectives:Behavioral and psychological symptoms of dementia (BPSD) are nearly universal in dementia, a condition occurring in more than 40 million people worldwide. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of living alone with dementia and other progressive neurological conditions: findings from primary care data in England

✓ Peer-reviewed alzhub usefulness score 49 out of 100. BMC Medicine 2025-11-04

In 2023, there were 205,507 people with dementia in the CPRD database, 40,244 with Parkinson's disease, 3515 with MND and 1672 with Huntington's disease. 5 key findings →

Participants: 205,507 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations between falls and other serious adverse events and antihypertensive medication in individuals with dementia: An observational cohort study

✓ Peer-reviewed alzhub usefulness score 49 out of 100. PLoS Medicine 2025-09-17

This was a retrospective analysis using nationally representative UK general practice population between 1998 and 2018, from electronic health records (Clinical Practice Research Datalink, CPRD, GOLD). 5 key findings →

Participants: 1,219,732 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Drug repositioning and repurposing for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Nature reviews. Neurology 2020-09-16

Drug repositioning and repurposing can enhance traditional drug development efforts and could accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia and mild cognitive impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Vascular risk factor associations with subjective cognitive decline and mild behavioural impairment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Brain Communications 2025-01-01

Having three or more vascular risk factors (odds ratio = 1.23, 95% confidence interval [1.04-1.47]), actively smoking (odds ratio = 1.54, 95% confidence interval [1.29-1.82]), being overweight (odds ratio = 1.46, 95% confidence interval [1.22-1.74]), and having diabetes (odds ratio = 1.29, 95% confidence interval [1.09-1.53]) were associated with higher odds of subjective cognitive decline. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of neurology 2026-09-07

Synaptic dysfunction is increasingly recognized as an early and biologically relevant component of α-synucleinopathies. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioural Impairment in the Revised NIA-AA Research Framework

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of geriatric psychiatry and neurology 2025-08-13

BackgroundAs the prevalence of Alzheimer disease (AD) rises, early identification of at-risk individuals is essential for effective intervention. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Overactive bladder medications and risk of emergency hospital admissions with delirium in adults without dementia: self-controlled case series

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Age and Ageing 2025-08-29

The risk of delirium admissions was elevated for the first 1-30 days of prescriptions [IRR 1.54 (95% CI 1.30-1.82) for men, 1.44 (1.22-1.70) for women] and whilst reducing over time for women [1.10 (0.94-1.29) for 91-365 days of prescriptions], it remained elevated for men [1.38 (1.17-1.64)]. 5 key findings →

Participants: 293 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Transcriptomic analysis of plasma small extracellular vesicles identifies potential diagnostic biomarkers for Parkinson's disease dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Parkinsonism & Related Disorders 2025-12-09

We identified 51 transcriptome-wide significant (edgeR q < 0.05) DEGs, compared to controls, and 26 transcriptome-wide significant DEGs, compared to PD, in PDD plasma SEV. 5 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk of stroke associated with risperidone in dementia with and without comorbid cardiovascular disease: population-based matched cohort study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The British Journal of Psychiatry 2025-10-09

In the overall cohort (28 403 risperidone users and 136 324 mtatched controls), risperidone was associated with increased risk of stroke (adjusted hazard ratio: 1.28; 95% CI: 1.20-1.37). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Understanding rehabilitation and support needs after an episode of delirium: a qualitative thematic analysis of interviews with older people with delirium, family carers and healthcare professionals

✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMC Geriatrics 2025-07-26

Several interconnected themes were identified as potential resources that enable recovery from delirium: (a) social contact and recovery of social lives; (b) the need for information, support, and education; (c) personalisation and personhood; (d) relationship continuity with professional carers; (e) the experience and involvement of carers; and (f) treating the cause and healthy lifestyle. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cytoplasmic expression of trans-active response DNA-binding protein-43 in aged mice display hippocampal sclerosis-like degeneration and neuronal loss with reduced lifespan

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Neuropathology & Experimental Neurology 2025-01-26

Trans-active response DNA-binding protein-43 (TDP-43) is the major pathological protein in motor neuron disease and TDP-43 pathology has been described in the brains of up to 50% of patients with Alzheimer disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-03

Alzheimer's disease progresses heterogeneously across diverse cohorts, yet current predictive models fail to capture this complexity while remaining clinically interpretable. 4 key findings →

Design: longitudinal study Participants: 1,669 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model

⚠ Report — not peer-reviewed alzhub usefulness score 16 out of 100. Health technology assessment (Winchester, England) 2012-01-01

Alzheimer’s disease (AD) is the most commonly occurring form of dementia. 4 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Perceptions of non-invasive brain stimulation and barriers to it's clinical translation: a multi-stakeholder focus group study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-26

ObjectivesNon-invasive brain stimulation (NIBS) holds significant promise for treating neurological and neuropsychiatric conditions, yet translation into routine clinical practice remains limited. 1 key finding →

Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed